Slide 1: Cover letter to stock exchanges: Investor / Analysts Presentation
November 9, 2024 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q2FY25
Aurobindo Pharma Limited Earnings Presentation Q2FY25
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q2FY25 Business & Financial Highlights Update on Biosimilars, Peptides, 11 Vaccines and CMO space 14 Financial Summary 13 17 Filings Snapshot 3
Slide 5: Q2FY25 Business & Financial Highlights
Q2FY25 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q2FY25 ₹ 7,796 Cr ₹ 1,566 Cr ₹ 817 Cr Q2FY24 ₹ 7,219 Cr ₹ 1,403 Cr ₹ 752 Cr Y-o-Y growth % 8.0% 11.6% 8.6% 5
Slide 7: Business Highlights – Q2FY25
Business Highlights – Q2FY25 Base business (excl. the transient and long-term business-related impact) revenue grew by 7% QoQ Base EBITDA margin stood around 21% and absolute EBITDA grew in double digit QoQ Net Capex of US$ 80 million* primarily towards capacity enhancements Total R&D (incl. depreci
Slide 8: Quarterly Performance – Q2FY25
Quarterly Performance – Q2FY25 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 7,796 451 7,580 7,567 432 426 7,352 421 7,219 409 6,851 382 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 EBITDA (Rs Crore) Net Debt to Equity 1,601 1,687 1,620 1,566 0.0
Slide 9: Consolidated Business Performance
Consolidated Business Performance ₹ Crores Q2FY25 Q2FY24 Y-o-Y (%) Q1FY25 Q-o-Q (%) USA** 3,530 3,385 4.3% 3,555 -0.7% Europe 2,105 1,769 19.0% 1,982 6.2% Growth Markets* 812 564 44.0% 709 14.4% ARV 193 250 -22.8% 229 -15.6% Total Formulations 6,640 5,968 11.3% 6,475 2.5% Beta-lactam 837 816 2.5% 79
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 430 426 425 421 420 • US revenue in Q2FY25 increased by 2.9% YoY and decreased by 415 409 1.1% QoQ to USD 421 Mn, accounting for 45.3% of 410 405 consolidated revenue 400 Q2FY24 Q1FY25 Q2FY25 • Specia
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 229 1,166 1,156 221 1,092 197 97 85 68 30 27 23 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Growth Markets posted revenues of Europe business posted revenues of ARV
Slide 12: Update on Biosimilars, Peptides, Vaccines and CMO space
Update on Biosimilars, Peptides, Vaccines and CMO space 11
Slide 13: Continuing to advance our efforts in biosimilars, peptides, vaccines and CMO space
Continuing to advance our efforts in biosimilars, peptides, vaccines and CMO space Biosimilars CMO Peptides and Vaccines • Advancing our oncology and immunology • The civil works have commenced for our • 14 DMFs filed in peptides biosimilars large-scale CMO facility for mammalian • First-in-class li
Slide 14: Biosimilars pipeline update
Biosimilars pipeline update Key Products Therapy Current Status (mkt size in USD Bn) Segment • Phase 1 PK/PD clinical study completed. Multi center and multi country Phase 3 study BP01 (6.2 bn) Oncology in NSCLC patients is in progress • MA received in India. Have applied for Manufacturing License •
Slide 15: Financial Summary
Financial Summary 14
Slide 16: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement Rs Cr Q2FY25 Q2FY24 YoY Chg. (%) Q1FY25 QoQ Chg. (%) Revenue from Operations 7,796 7,219 8.0% 7,567 3.0% Gross Profit 4,586 3,983 15.1% 4,494 2.0% Gross Margin 58.8% 55.2% 366 bps 59.4% -57 bps Overheads -3,020 -2,579 17.1% -2,875 5.0% EBITDA (before Fore
Slide 17: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-21 Mar-22 Mar-23 Mar-24 Sep-24 Closing Rate (INR/USD) 73.110 75.793 82.170 83.405 83.797 592 752 815 758 833 966 Fx Loan restated in INR 4,929 2,223 4,638 3,994 4,961 Rupee Loan 44 150 224 2,234 3,135 232 196 Gross Debt 4,972 2,373 4,862 6,318
Slide 18: Filing Snapshot
Filing Snapshot 17
Slide 19: US ANDA Filings Snapshot as on 30th September 2024
US ANDA Filings Snapshot as on 30th September 2024 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 154 27.1 Aurobindo (Excl. Specialty & 800 676 506 600 Specialty & Injectables 300 700 ARV 29 0.4 600 500 250 500 200 170 Injectables) 400 400 150 47.2 300 300 146 CVS 121 200 200 115 1
Slide 20: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Sep 24 US* 429 478 541 586 639 727 774 830 848 FA: 676, TA:26 Europe** 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,642 3,817 2,5
Slide 21: Thank You
Thank You Digitally signed by BADDIGAM ADI REDDY Date: 2024.11.09 18:57:02 +05'30' For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 20